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Objective: To evaluate the effect of different concentrations of inhaled budesonide on
secretion of tumoral necrosis factor-alpha (TNF-a) and on ligature-induced alveolar bone
loss in Wistar rats.
Materials and methods: Forty-two animals were randomly divided in four groups. Control
group (G1) did not receive any procedure. For the other 3 groups, alveolar bone loss was
induced by placement of ligatures around the upper second molar. The contralateral molar
was considered intra-group control. Group 2 (G2) was nebulized with saline solution (NaCl
0.9%). Groups 3 and 4 (G3 and G4) were nebulized with 30 mg and 100 mg budesonide,
respectively. Administration of drugs was performed daily for 14 days. Blood samples were
collected from all animals for analysis of TNF-a. The maxillae from G2, G3 and G4 were
removed and defleshed with 9% sodium hypochlorite. Morphometric analysis of bone loss
was performed in digital standard photographs. Statistical analysis was performed with
one-way ANOVA, followed by Tukey HSD or Scheffe´multiple comparison’s test (significance
level P  0.05).
Results: Mean alveolar bone loss values for teeth with ligature were 0.72, 0.70 and 0.77 mm
for Groups 2, 3 and 4, respectively. No statistically significant differences were found
amongst groups with or without ligature. The production of TNF-a was 60% higher in
the presence of ligature (G1 vs. G2/G3/G4). No effect was observed in TNF-a secretion after
inhalation of budesonide.
Conclusion: Inhaled budesonide in different concentrations did not alter alveolar bone loss
and TNF-a secretion in male Wistar rats.
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Budesonide is a glucocorticosteroid with local anti-inflamma-
tory effect when used through the respiratory tract. By means* Corresponding author at: Rua Ramiro Barcelos, 2492–CEP: 90035-003, 
E-mail address: dudagaio@me.com (E.J. Gaio).
0003–9969      # 2011 Elsevier Ltd. 
doi:10.1016/j.archoralbio.2011.04.018
Open access under the Elsevier OA license.of inhalation, it leads to immediate relief of breath problems in
asthmatic patients. Its anti-inflammatory effect involves T
cells, eosinophils, and mast cells. It provokes inhibition of the
anti-inflammatory mediators and the immune responses.1
The pathogenesis of periodontal diseases is characterized byPorto Alegre, RS, Brazil. Tel.: +55 51 33085318; fax: +55 51 33085318.
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causing destruction of periodontal ligament and alveolar bone
loss.2 Amplification of this initial localized response results in
the release of cytokines (e.g. TNF-a) and other mediators and
propagation of inflammation through the gingival tissue.3 In the
US adult population, the prevalence of asthma and periodontitis
can reach 11% and 35%, respectively.4,5
There are several studies considering the effects of non-
steroidal anti-inflammatory drugs (NSAID) as modulators of
periodontal disease.6,7 They are supposed to reduce matrix
metalloproteinases and prostaglandin production, which
could be associated with reduced periodontal breakdown.
On the other hand, studies concerning steroidal anti-inflam-
matory drugs are scarce.8 Cavagni et al.9 reported increased
tissue destruction when evaluating the effect of systemic
dexamethasone in rats. von Wowern et al.10 showed reduction
in the mandibular bone mineral content following systemic
corticosteroid treatment.
Studies evaluating the effects of inhaled anti-inflammatory
drugs on the periodontium are scarce in the literature.
Moreover, it is not clear whether a regimen of exposure of
either the steroid or beta-agonist to localized action might
have some direct or indirect effect on the production of
cytokines. The hypothesis of the present study is that
inhalation of budesonide could modulate periodontal break-
down through reduction of TNF-a. The aim of the present
study was to evaluate the effect of inhaled budesonide in
different concentrations on TNF-a production and on ligature-
induced alveolar bone loss in Wistar rats.
2. Materials and methods
A randomized, blind, and controlled animal study was
performed. The research protocol was approved (protocol
number 2008128, Sep 24 2009) by the Ethical and Research
Committee of the Federal University of Rio Grande do Sul,
Brazil.
2.1. Sample size calculation
The sample size estimate was based on the variability of data
from a previous study,9 which evaluated a systemic cortico-
steroid in a ligature-induced periodontal disease model
assessed by morphometric analysis. We assumed as relevant
a difference of 0.16 mm in mean bone loss between groups.
Considering Type I and Type II errors of 5% and 20%,
respectively, it was estimated a sample size of 9 animals
per group.
2.2. Experimental groups
Forty-two male adult (60 days old) Wistar rats (mean weight of
225 g) were used in the present study. The animals remained
during the experimental period at the Animal Reproduction
and Experimentation Centre (CREAL), submitted to a 12-h
dark/light cycle. Four to five animals were housed in each cage
at a controlled temperature of around 20 8C. Standard rat chew
pellets (Nuvilab1, Curitiba, Brazil) and water ad libitum were
given to all animals. The animals were randomly assigned toone of the four study groups by means of draw. Control group
was not exposed to any procedure during the experiment (G1,
n = 12). The test groups were submitted to inhalation saline
solution (G2, n = 10), budesonide 30 mg (G3, n = 10), and
budesonide 100 mg (G4, n = 10), during a 14-day period. All
the solutions were administered to the rats once a day.
2.3. Previous procedures
In order to minimize stress generated by novelty effect, the
animals were submitted to the forced ventilation chamber
without nebulization for 5 min during 4 days, before the
beginning of the experimental period.
2.4. Induction of alveolar bone loss
Besides the inhalatory treatment, all animals were submit-
ted to the model of induction of alveolar bone loss. Cotton
ligatures (Ethicon, Johnson & Johnson, Sa˜o Paulo, Brazil)
were placed around the second maxillary molars on the
right side under general anaesthesia with xylazine/keta-
mine (10 mg/kg—1:1). The contra-lateral teeth (that were not
submitted to any manipulation) were considered for control
analysis.11–14
2.5. Forced ventilation chamber
To administrate the inhalatory solutions to the animals, a
ventilation chamber was built according to a previous study.15
It consisted in a 3 mm thickness acrylic transparent cage
(22 cm  22 cm  22 cm), divided into four cells with the same
space each one and covered by a removable lid of the same
material. A hole was present in the centre of the lid. The cage
was connected to a nebulizer through a 5 mm diameter hose.
2.6. Preparation of the solutions
The researchers prepared the solutions. Based on 5 min
nebulization capacity of the nebulizer (1.1 ml), 2.7 ml of
budesonide (Pulmicort1, 0.5 mg/ml, AstraZeneca, Sa˜o Paulo,
Brazil) was diluted in 97.3 ml of saline solution (NaCl 0.9%) for
G3. For G4, 9.1 ml of budesonide was diluted in 90.9 ml of NaCl
0.9%.
2.7. Inhalation treatment
The rats were placed in the cage that was covered and sealed
with adhesive tape, to minimize possible loss of medication
during the nebulization procedure. After that, the animals
were maintained for 1 min extra to dissipate the solution in
the cage. Following, the chamber was cleaned with water and
soap to remove deposits of the medication on the walls. All the
procedures were performed in the morning, once a day, at the
same time, during 14 days.
To ensure proper operation of the apparatus, nebulization
was performed without the animals in the cage in order to
verify the nebulization volume during the experimental
period once a week. Additionally, the residual volume in
the reservoir was measured to verify possible alterations in
the apparatus.
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Body weight was measured (in grams) to evaluate animals
general health at days 0, 7, and 14, during the experimental
period.
2.9. Cytokine enzyme-linked immunosorbent assay
(ELISA)
The animals were killed by decapitation. Such procedure was
performed 24 h after the last administration of the medica-
tion/saline solution. The levels of TNF-a in supernatants were
determined by ELISA using commercial anti-cytokine anti-
body pairs (Becton Dickson, Pharmingen, San Jose, CA, USA),
according to the manufacturer’s protocols. Human recombi-
nant TNF-a (Becton Dickson, Pharmingen, San Jose, CA, USA)
was used to generate standard curves. Briefly, polystyrene
high-binding 96-well microtiter plates (Nunc-Immuno Plate:
Maxisorp, Nalge Nunc, Rochester, NY, USA) were coated with
capture antibody for each individual cytokine. After over-
night incubation at 4 8C, the plates were washed (as in
subsequent steps) with phosphate-buffered saline contain-
ing 0.05% Tween 20 and 0.4 M NaCl, and then incubated, for
2 h at room temperature, with diluent buffer (phosphate-
buffered saline containing 1.0% bovine serum albumin;
100 mL per well) to block non-specific binding. After washing,
samples (100 mL per well) or the serially diluted standards of
each cytokine were added to the plates, which were then
incubated overnight at 4 8C. After washing the plates, 100 mL
of biotinylated antibody was added to each well and the plates
were incubated for 1 h at room temperature. Colour was
developed by the use of peroxidase-conjugated streptavidin
(1:200; 100 mL per well) (DAKO Corp., Carpinteria, CA, USA) for
30 min. After washing, the chromogen [o-fenilenodiamine-
2HCL (Sigma, St. Louis, MO, USA)] was added and incubation
continued for 15 min. The reactions were stopped with 150 mL
of 1.0 M H2SO4, and the absorbances were measured at
490 nm by ELISA reader. Calibration curves were plotted by
regression analysis, and the optical density of each sample
was used to estimate the concentration of each cytokine per
well. The minimum detectable dose (sensitivity) for all
cytokines was 15.625 pg/mL. Dilution factors were 1:10 for
TNF-a and IL-10; 1:100 for IL-6 and 1:50 for IL-8. Samples with
cytokine levels below the detection limit of assay were scored
as 0 pg. The tests were performed in duplicate for each
sample.
2.10. Morphometric analysis
The maxillae were removed and defleshed in sodium
hypochlorite with 9% active chlorine (Mazzarollo, Gravataı´,
Brazil) for 5 h. After rinsing, the specimens were stained
during 1 min in methylene blue 1% (Quinta Esseˆncia, Porto
Alegre, Brazil) to delineate the cemento-enamel junc-
tion.11,16,17 Photographs were taken using a 6.1 megapixel
digital camera (Nikon1 Coolpix, Ayutthaya, Thailand) coupled
to a tripod with macro 100 lenses with minimal focal distance.
The specimens were placed with the occlusal surface parallel
to the floor. Pictures were taken from the buccal and palatal
aspects of each specimen.A calibrated and blind examiner for the experimental
groups performed the measurements in the pictures (dis-
tances from cemento-enamel junction to the bone crest) with
the aid of Image Tool 3.0 software (UTHSCPA, San Antonio, TX,
USA). The bone level was measured in 5 points at the mesial,
medial and distal aspects of the second maxillary molar,
buccally and palatally, on both sides (with or without
ligatures). Such procedures were performed according to
Fernandes et al.17
2.11. Blinding
Prior to morphometric analysis, all the pictures were coded to
ensure blindness. After analysis, the codes were broken and
the pictures renamed to their experimental group.
2.12. Reproducibility
Before the morphometric analysis the reproducibility was
performed, by double measurement of 10% of the pictures by
the same examiner (EJG). Picture’s choice was made randomly
after a one-week interval. The intra-class correlation coeffi-
cient (ICC) between the measurements was 0.99, which is
considered excellent.
2.13. Statistical analysis
After verification of normal distribution of data, the analysis
was performed using a software package (SPSS Inc., version
12.0, Chicago, IL, USA). Mean and standard deviations (SD) of
body weight, alveolar bone loss and TNF-a were measured. All
comparisons were performed using one-way ANOVA followed
by Tukey HSD or Scheffe` post hoc test when indicated. The
level of significance was set at 5%, and the unit of analysis was
the animal.
3. Results
Fig. 1 shows the mean weight of the test animals during the
experimental period. All groups gained around 50 g during the
study and there were no statistically significant differences
amongst the groups.
The effect of different concentrations of budesonide or
saline solution inhaled on alveolar bone loss (expressed in
millimetres) is showed in Table 1. It was observed that teeth
with ligature showed greater mean alveolar bone loss when
compared to the teeth without ligature (P < 0.05). The pattern
of alveolar bone loss was somewhat similar for the three test
groups. Teeth with ligature showed mean values of bone loss
of 0.72, 0.70 and 0.77 mm for Groups 2, 3 and 4, respectively. No
statistically significant differences amongst the groups were
observed. In teeth without ligatures, mean values of 0.27, 0.25
and 0.27 mm were observed for Groups 2, 3 and 4, respectively.
Similarly, no statistically significant differences were found
amongst groups.
Mean values of TNF-a in the four experimental groups are
shown in Fig. 2. Induction of alveolar bone loss in G2 increased
around 60% the secretion of this inflammatory cytokine, when
compared to the control group (G1). Nevertheless, this
Fig. 1 – Mean body weight (g) for the three test groups during the study.
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ent concentrations of inhaled budesonide (30 or 100 mg/daily)
were not able to alter the secretion of TNF-a expressed in the
presence of periodontal inflammation (see G3 and G4 vs. G2).
No statistically significant differences in this score were
observed in the groups treated with budesonide.
4. Discussion
The present study evaluated ligature-induced alveolar bone
loss in rats submitted to different concentrations of inhaled
budesonide, compared to a group that inhaled saline solution.
There is no similar study in the literature. No statistically
significant differences in alveolar bone loss amongst the
groups were observed. This finding could be associated to the
absence of biological effect of budesonide on periodontal
breakdown. On the other hand, recent work has demonstrated
that, in addition to bacterial control, modulation of the host’s
immuno-inflammatory response is also capable of controlling
periodontitis.18,19
The choice for male rats tried to avoid hormonal factors
that could negatively interfere in the results.20 The allocation
of rats was performed at random also to allow for equal
chances of being included in each group. Additionally,
measurements in the morphometric analysis were performed
by a calibrated and blinded examiner. The intra-class
correlation coefficient of the examiner warrants excellent
levels of reproducibility. Moreover, recent studies indicate that
alveolar bone loss in mice and rats can be accurately
quantified using microscopic evaluation, morphometric anal-Table 1 – Mean alveolar bone loss (millimetres WSD) on
the different experimental test groups.
Groups Without ligature With ligature
Buccal Palatal Buccal Palatal
Group 2 0.24  0.09a 0.30  0.05a 0.86  0.22b 0.58  0.17b
Group 3 0.20  0.04a 0.31  0.06a 0.79  0.15b 0.61  0.14b
Group 4 0.28  0.11a 0.27  0.05a 0.95  0.35b 0.59  0.16b
Analysis of variance—Scheffe. Distinct letters mean intra-group
significant difference.ysis, or microcomputed tomography with no significant
variations in outcomes.17,21
To evaluate general health, rats were weighted weekly
throughout the study. It is possible to infer that the general
health remained good, since no statistically significant
differences were found amongst groups during the experi-
mental period. Ligature-induced periodontal breakdown
and this model are widely used in the literature.11,14,16,22
The experimental period of ligature in the literature varies
from 15 to 60 days. The period used in our study was based
in data from a previous report, which showed that the main
intra-group differences were found in the first 15 days.23
After this period, the differences levelled off. Additionally,
similar pattern of bone loss was described in studies that
used the same methodology and an experimental period
of approximately 30 days.10,12,14 The observed statistically
significant differences amongst teeth with and without
ligatures support that the period of 15 days was sufficient.
In relation to the corticosteroid administration (inhalation),
Elias et al.15 verified that a forced ventilation chamber is an
effective way for inhalation of steroidal anti-inflammatory
drugs in rats. Despite the fact that histometric analysis has
been used to measure bone loss in rats, morphometric
analysis is an important tool validated in literature and today
is used more frequently.11,17,21 It can be an alternative to
histometric analysis if the study aims to measure the bone
loss. This is related to the ease of the technique and also to the
fact that the direct view of defects can be made in this type of
analysis without interference from the cutting plans of
histological sections.24Fig. 2 – TNF-a expression in the different experimental
groups.
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study were chosen in accordance with previous studies.15,25,26
The dose of 30 mg/ml was the concentration that caused
behaviour alterations in animals, and 100 mg/ml was the lowest
therapeutic dose used for asthma treatment in humans. We
analysed different concentrations of the medication to verify a
possible dose–response relationship. However, the results
showed no dose–response relationship in this study.
In the present study, a different pattern of alveolar bone
loss amongst experimental groups was not detected. Since the
administration of corticosteroids was performed according to
a validated method, it should not be interpreted, therefore,
that the absence of significant differences could be due to non-
absorption of medications systemically. We suppose that this
fact might be due to inhaled administration of the corticos-
teroids having a topic anti-inflammatory effect, promoting
lower systemic concentrations of the drug. Even if some
adverse effects were expected by the corticosteroid adminis-
tration, they are less pronounced when compared to other
ways such as injections or via gastric administration.27 This is
the specific reason why we used topical administration.
Additionally, the specific research hypothesis was related to
the possible adverse effects in the periodontium when
corticosteroids are inhaled such as in asthma treatments,
for example.
There is an increase production of TNF-a in G2 as compared
to G1. This finding was in agreement with the literature.28 This
was probably due to the presence of periodontal inflamma-
tion, which reinforces that periodontal disease is a systemic
problem.29,30 No effect in TNF-a production was observed
when G3 and G4 are analysed. This also strengthens the idea
that inhaled steroids have little systemic anti-inflammatory
effect.31 On the other hand, the literature has shown that
budesonide has a high level of topical anti-inflammatory
activity.32 Nevertheless, this topical glucocorticoid was not
able to modulate the periodontal breakdown.
The results of the present study can contribute for better
understanding of the pathogenesis of alveolar bone loss. Data
suggest that inhaled corticosteroid does not significantly
interfere in the mechanisms of bone loss. This can be
interpreted that budesonide does not have a promising effect
as a modulator of host response to future studies such as other
anti-inflammatory drugs.7,33,34 Additional studies evaluating
effects of budesonide in oral mucosa are encouraged. We
concluded that different concentrations of inhaled budeso-
nide do not interfere in the ligature-induced alveolar bone loss
in Wistar rats. Additionally, no effect of budesonide was
observed in TNF-a production.
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